Janux Therapeutics announced that it has nominated a development candidate under its exclusive worldwide license agreement with Bristol‑Myers Squibb, triggering a $35 million milestone payment to the company. The payment reflects progress toward advancing the candidate into clinical development and underscores Bristol‑Myers Squibb’s continued investment in third‑party platforms to diversify its oncology pipeline.
The collaboration centers on Janux’s TRACTr platform, which engineers tumor‑activated T‑cell engagers that mask the T‑cell binding domain until activated by tumor‑specific proteases. Janux is responsible for preclinical development up to IND submission, while Bristol‑Myers Squibb will take over clinical development and commercialization. The target antigen for the candidate remains undisclosed, but the platform is designed to improve safety and efficacy in solid tumors compared to traditional T‑cell engagers.
Bristol‑Myers Squibb is pursuing this partnership as part of a broader strategy to replace legacy revenue that has been eroding due to patent expirations on key drugs such as Revlimid, Pomalyst and Eliquis. In 2025, the company’s legacy portfolio revenue fell 15‑18%, while its growth portfolio surged 17%. The company’s growth portfolio includes immuno‑oncology drugs like Opdualag and Breyanzi, hematology offerings such as Reblozyl, and the heart drug Camzyos. Acquisitions of Mirati, Karuna and RayzeBio, along with collaborations such as the one with Merck, further diversify its pipeline.
"This milestone underscores the strength of our approach to generating value through both internal innovation and strategic partnerships, and reflects the continued promise of our tumor‑activated platforms. The nomination of a development candidate highlights our ability to translate platform insights into differentiated therapeutics in collaboration with leading oncology companies," said David Campbell, President and CEO of Janux.
"We made significant progress in 2025, with real momentum in our growth portfolio and a strengthened balance sheet that provides the strategic flexibility to continue investing in growth drivers. 2026 is data‑rich, and we are advancing a truly differentiated pipeline with multiple pivotal readouts expected in the back half of the year. Our core business is strong and growing, and we have the potential to achieve industry‑leading, sustainable growth into the…" said Chris Boerner, CEO of Bristol‑Myers Squibb.
The $35 million payment validates Janux’s TRACTr platform and provides the company with additional resources to accelerate preclinical work. Janux is eligible for further development, regulatory and commercial milestone payments that could total up to approximately $800 million, as well as tiered royalties on global product sales. The company also has other clinical programs, including JANX007 (PSMA‑TRACTr) and JANX008 (EGFR‑TRACTr) in Phase 1 trials, and JANX011 (CD19‑ARM) for autoimmune diseases. The milestone positions Bristol‑Myers Squibb to potentially share in future commercial upside if the candidate progresses, reinforcing its strategy to diversify its oncology pipeline and replace legacy revenue streams.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.